Lundabolaget ImmuneBiotech har erhållit 500.000 kronor i Fas 1 av EU:s Horizon 2020 SME instrument
för att undersöka potentialen av sin probiotiska produkt, GutMagnificTM inom ytterligare ett område: mot kroniskt trötthetssyndrom, ME/CFS. ImmuneBiotech får senare, efter detta erkännande i Fas 1, även möjlighet att söka medel i Fas 2 och då handlar det om 5-25 miljoner kronor.
(Resterande text i pressmeddelandet följer här på engelska: )
ImmuneBiotech gets EU Horizon 2020 grant
ImmuneBiotech Medical Sweden AB, the probiotic and microbiome company developing and marketing science-based probiotics, is pleased to announce it has received a Phase 1 grant of €50.000 from the European Innovation Council Horizon 2020 SME Instrument program.
The grant will be used to investigate the business feasibility of ImmuneBiotech’s probiotic product GutMagnificTM in Myalgic Encephalomyelitis, also called Chronic Fatigue Syndrome (ME/CFS). GutMagnificTM is a super-consortium of five probiotic strains scientifically designed to address the underlying key causes of Irritable Bowel Syndrome (IBS). The product also has potential in other conditions such as ME/CFS, which is a debilitating, multi system disease, characterized by unexplained persistent and relapsing fatigue and a combination of accompanying symptoms like IBS. The FDA has described this condition as “serious and life-threatening” with no current treatments. The global prevalence is between 0.2-1%, a higher prevalence than many chronic inflammatory conditions and cancer forms.
The EU selected ImmuneBiotech out of 2 822 applications based on criteria such as the high need for the innovation, a highly innovative solution that goes beyond the start of art, and the excellent experience of our team.
“I’m extremely pleased that ImmuneBiotech was selected by the European Commission. This is another external proof that our 15 years of experience in probiotics, immunology, microbiology and research on the gut-brain-axis is paying off in highly innovative probiotic products.” said Shahram Lavasani, CEO of ImmuneBiotech.
ImmuneBiotech is an alumnus company of SmiLe Incubator, a business incubator in the life sciences that offers business consulting, well-equipped laboratories and a community www.smileincubator.life .
About ImmuneBiotech Medical AB
ImmuneBiotech discovers and markets science-based probiotic food supplements. Based on our multi-disciplinary scientific foundation, we deliver innovative probiotic products scientifically designed to modulate the gut microbiota, reduce gut permeability and reduce inflammation.
GutMagnificTM is a super-consortium of five probiotic strains scientifically designed to address the underlying key causes of IBS. It is a patent pending combination of proprietary lactobacillus strains and will be sold as a food supplement supported by clinical data. GutMagnificTM has potential application in several other severe and prevalent conditions such as diarrhea, antibiotic induced diarrhea, Clostridium difficile infection (CDI) and Chronic Fatigue Syndrome (ME/CFS). Is has also the ability to target symptoms such as leaky gut and small intestine bacterial overgrowth (SIBO).
About the European Commission’s SME Instrument
The SME Instrument is part of the European Innovation Council (EIC) pilot that
supports top-class innovators, entrepreneurs, small companies and scientists with funding opportunities and acceleration services.
Companies can apply for two distinct phases under the SME Instrument, depending on the maturity of their innovation. Under Phase 1 of SME Instrument, each project will receive a lump-sum of €50.000 to carry out a feasibility study. Under Phase 2, each project will receive from €0.5 to €2.5 million to finance innovation activities such as demonstration, testing, piloting and scaling up. In addition, companies under both phases can benefit from free coaching and business acceleration services.
For more information: read here
Shahram Lavasani, CEO
ImmuneBiotech Medical AB
+46 707 40 86 61